Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Latuda Approved for Bipolar Depression in Canada: DSP
April 7, 2014
- Gilead’s Novel Hepatitis C Drug Beats Primary Endpoint in PIII, Filing Slated for Mid-Year
April 7, 2014
- Novartis Replaces Japan Unit Head amid SIGN Trial Probe
April 4, 2014
- Sanofi Japan Sales Down 3.9% as Generics Take Toll
April 4, 2014
- Daiichi Sankyo Initiates Multinational ENSURE-AF Study of Edoxaban in the US, Europe
April 4, 2014
- Sawai Stands Out with Operating Profit Rate of 25% in 3rd Quarter, Moving into Top Level of the Industry
April 4, 2014
- Sales Rep Wrote Out Side Effect Grades for Doctors in SIGN Trial: Panel
April 3, 2014
- Independent Panel Finds Transgression of Fair Competition Code, Cover-Up over SIGN Trial
April 3, 2014
- COO Weber Wants Takeda to Be Global Leader
April 3, 2014
- Mochida Aims for Sales of 110 Billion Yen with Generic Sales of Over 10 Billion Yen in FY2016
April 3, 2014
- Astellas Establishes “Regenerative Medicine Unit”; Aims to Establish Basic Technologies within 1 to 2 Years
April 3, 2014
- 2014 Japan Debut of Prostate Cancer Drugs to End Dearth of CRPC Treatments
April 2, 2014
- Latuda Granted European Regulatory Approval: DSP, Takeda
April 2, 2014
- Abbott Japan Takes Over Marketing Approval for Duphaston from Daiichi Sankyo
April 2, 2014
- Kyowa Kirin Files Nesp in Japan for Anemia in Myelodysplastic Syndrome
April 2, 2014
- Japan Vaccine Files NDA for Pneumococcal Conjugate Vaccine in Japan
April 2, 2014
- US Biotech NPS Takes Aim at Japan Debut around 2017
April 1, 2014
- Torii Puts Off Launch of Sublingual Hay Fever Drug
April 1, 2014
- Otsuka Acquires Rights for Dacogen from Eisai US Subsidiary
April 1, 2014
- Shionogi Predicts Milder Patent Cliff for Crestor after AZ Deal: Pres.
March 31, 2014
ページ
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…